All Stories

  1. Shared genetic and environmental influences on altered functional connectivity and schizophrenia liability
  2. Obesity and Schizophrenia: Results of a Feasibility Study with Semaglutide to Assist Weight Loss
  3. Further evidence for the association between childhood trauma and suicidal ideation in young individuals: A twin based study
  4. The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force
  5. The Moderating Role of Genetic and Environmental Risk Factors for Schizophrenia on the Relationship between Autistic Traits and Psychosis Expression in the General Population
  6. Attenuated mental symptoms in the general population: first data from the observational cross-sectional ATTENTION study in Greece
  7. End-of-life care for people with severe and persistent mental illness and a life-limiting disease: An umbrella review
  8. Prevalence, nature, and determinants of COVID-19-related conspiracy theories among healthcare workers: a scoping review
  9. The epidemiology and phenomenology of non-antipsychotic-induced dystonia: a hybrid systematic-narrative review
  10. The association between aberrant salience and psychotic experiences in general population twins, and genetic vulnerability as a modifier
  11. Characterizing the dynamics, reactivity and controllability of moods in depression with a Kalman filter
  12. Impact of a Vision-Based Smoothing Filter on Schizophrenia Classification
  13. Homelessness and housing problems in admitted psychiatric patients in Flanders, Belgium
  14. 改善精神疾病患者之安樂死管控:從比利時看安樂死的刑事法院判決(二)
  15. 比利時案例認定為精神疾病患者安樂死並不違反歐洲人權公約
  16. Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review
  17. Euthanasia for unbearable suffering caused by a psychiatric disorder: improving the regulatory framework
  18. Functional neurological disorder: defying dualism
  19. Alert prescribing of clozapine: a comparison of five drug–drug interaction sources
  20. E-book: Ethiek en gezondheidsrecht - Uitgave 2023
  21. Associations between childhood adversity, psychiatric symptoms, and self‐esteem outcomes in adolescents and young adults: An experience sampling study
  22. Gender differences in the associations between childhood adversity and psychopathology in the general population
  23. Viewpoint: Psychiatrists and other medical professionals in Belgium show a substantial lack of knowledge about poverty
  24. The within-person bidirectional association between physical activity and loneliness in the daily lives of adolescents and young adults
  25. Differential associations of childhood adversity subtypes and psychopathology in men and women
  26. Sustainability in Dutch and Flemish mental healthcare: A descriptive and comparative study
  27. Affective wellbeing moderates the association between polygenic risk score for neuroticism and change in neuroticism
  28. De Belgische Euthanasiewet doorstaat de mensenrechtelijke toets, behalve voor de a posteriori-controle (Mortier tegen België (nr. 78017/17))
  29. Coping and sleep quality in youth: An Experience Sampling study
  30. Media coverage of Belgium’s first criminal case concerning euthanasia for psychiatric patients: A content analysis of Flemish newspapers and magazines
  31. New Directions in the Ethics of Assisted Suicide and Euthanasia
  32. The Belgian euthanasia law under scrutiny of the highest courts
  33. Due Care in the Context of Euthanasia Requests by Persons with Psychiatric Illness: Lessons from a Recent Criminal Trial in Belgium
  34. Gene–environment interaction study on the polygenic risk score for neuroticism, childhood adversity, and parental bonding
  35. Prevalence and characteristics of registered falls in a Belgian University Psychiatric Hospital
  36. Klassieke psychedelica als behandeling voor depressie: waar staan we vandaag?
  37. The relationship between daily positive future thinking and past-week suicidal ideation in youth: An experience sampling study
  38. Falls Among Psychiatric Inpatients: A Systematic Review of Literature
  39. Severe Mental Illness and Cardiovascular Disease
  40. Improving control over euthanasia of persons with psychiatric illness: Lessons from the first Belgian criminal court case concerning euthanasia
  41. General psychopathology and its social correlates in the daily lives of youth
  42. Correction to: 49th ESCP virtual symposium on clinical pharmacy 19.10.2021–21.10.2021 Clinical pharmacy, working collaboratively in mental health care
  43. The relationship between daily positive future thinking and past-week suicidal ideation in youth: An experience sampling study
  44. Be(com)ing social: Daily-life social interactions and parental bonding.
  45. Barriers to Somatic Health Care for Persons With Severe Mental Illness in Belgium: A Qualitative Study of Patients' and Healthcare Professionals' Perspectives
  46. COVID-19-Related Mortality Risk in People With Severe Mental Illness: A Systematic and Critical Review
  47. Depression and post-traumatic stress disorder after perinatal loss in fathers: A systematic review
  48. Euthanasia of a person with a psychiatric disorder does not violate the European Convention on Human Rights (Mortier v. Belgium [no. 78017/17])
  49. COVID-19 Vaccination Rates in a Cohort Study of Patients With Mental Illness in Residential and Community Care
  50. Momentary Manifestations of Negative Symptoms as Predictors of Clinical Outcomes in People at High Risk for Psychosis: Experience Sampling Study
  51. COVID-19 vaccine uptake in patients with psychiatric disorders admitted to or residing in a university psychiatric hospital
  52. The complex and dynamic interplay between self-esteem, belongingness and physical activity in daily life: An experience sampling study in adolescence and young adulthood
  53. Major depressive disorder: a possible typisation according to serotonin, inflammation, and metabolic syndrome
  54. Emotion regulation in response to daily negative and positive events in youth: The role of event intensity and psychopathology
  55. Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study
  56. The Role of Working Memory in the Processing of Scalar Implicatures of Patients With Schizophrenia Spectrum and Other Psychotic Disorders
  57. COVID-19 vaccination for people with severe mental illness: why, what, and how?
  58. Network dynamics of momentary affect states and future course of psychopathology in adolescents
  59. Model-based PID-5 domain clusters and levels of impairment in self and interpersonal functioning
  60. The search for an autoimmune origin of psychotic disorders: Prevalence of autoantibodies against hippocampus antigens, glutamic acid decarboxylase and nuclear antigens
  61. The clinical characterization of the patient with primary psychosis aimed at personalization of management
  62. The Impact of Pharmacological and Non-Pharmacological Interventions to Improve Physical Health Outcomes in People With Schizophrenia: A Meta-Review of Meta-Analyses of Randomized Controlled Trials
  63. Stress reactivity as a putative mechanism linking childhood trauma with clinical outcomes in individuals at ultra-high-risk for psychosis: Findings from the EU-GEI High Risk Study
  64. Defining polypharmacy: in search of a more comprehensive determination method applied in a tertiary psychiatric hospital
  65. Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study
  66. Risk of Hospitalized Falls and Hip Fractures in 22,103 Older Adults Receiving Mental Health Care vs 161,603 Controls: A Large Cohort Study
  67. Links between the amount of antipsychotic medication prescribed per population at general practice level, local demographic factors and medication selection
  68. Prioritizing COVID ‐19 vaccination for people with severe mental illness
  69. Early warning signals in psychopathology: what do they tell?
  70. Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness
  71. Physical activity participation is associated with higher quality of life scores in men with alcohol use disorders: a study from Uganda
  72. The clinical characterization of the adult patient with depression aimed at personalization of management
  73. General psychopathology and its social correlates in the daily lives of youth
  74. Lower emotional complexity as a prospective predictor of psychopathology in adolescents from the general population.
  75. Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study
  76. Be(com)ing social: Daily-life social interactions and parental bonding
  77. Polygenic liability for schizophrenia and childhood adversity influences daily‐life emotion dysregulation and psychosis proneness
  78. Measuring resilience prospectively as the speed of affect recovery in daily life: a complex systems perspective on mental health
  79. Test-retest reliability, concurrent validity and correlates of the two-minute walk test in outpatients with psychosis
  80. TwinssCan — Gene-Environment Interaction in Psychotic and Depressive Intermediate Phenotypes: Risk and Protective Factors in a General Population Twin Sample
  81. Barriers, attitudes, confidence, and knowledge of nurses regarding metabolic health screening and intervention in people with mental illness: a pilot study from Uganda
  82. Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study
  83. The sublingual use of atropine in the treatment of clozapine‐induced sialorrhea: A systematic review
  84. Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study
  85. Reduced interhemispheric and increased intrahemispheric connectivity in schizophrenia brain networks
  86. A quantitative assessment of the views of mental health professionals on exercise for people with mental illness: perspectives from a low-resource setting
  87. Evidence for interaction between genetic liability and childhood trauma in the development of psychotic symptoms
  88. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis
  89. 7.3 POLYGENIC RISK FOR SCHIZOPHRENIA MODERATES THE INFLUENCE OF CHILDHOOD ADVERSITY ON DAILY-LIFE EMOTIONAL DYSREGULATION AND PSYCHOSIS PRONENESS
  90. Associations of the Built Environment With Physical Activity and Sedentary Time in Ugandan Outpatients With Mental Health Problems
  91. Health care professionals’ perspectives on physical activity within the Ugandan mental health care system
  92. Evidence that the association of childhood trauma with psychosis and related psychopathology is not explained by gene-environment correlation: A monozygotic twin differences approach
  93. Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study
  94. The impact of pharmacological and non‐pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta‐review of meta‐analyses of randomized controlled trials
  95. Alpha7 acetylcholine receptor autoantibodies are rare in sera of patients diagnosed with schizophrenia or bipolar disorder
  96. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study
  97. The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters Who Take On-label or Off-label Antipsychotic Medication
  98. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Ment...
  99. Patients with psychosis struggle with scalar implicatures
  100. S182. Evidence That the Polygenic Risk Score for Neuroticism Does Not Moderate the Impact of Childhood Trauma on Neuroticism: A GxE Model
  101. O42. Gene-Environment Correlation Does not Explain Away the Association Between Childhood Trauma and Psychopathology: A Monozygotic Twin Differences Approach
  102. Exercise self-efficacy correlates in people with psychosis
  103. O4.4. DOES POLYGENIC RISK SCORE FOR SCHIZOPHRENIA MODERATE THE MOMENTARY AFFECTIVE AND PSYCHOTIC REACTIONS TO DAILY-LIFE STRESSORS?
  104. The intriguing relationship between coronary heart disease and mental disorders
  105. Sensitivity to Peer Evaluation and Its Genetic and Environmental Determinants: Findings from a Population-Based Twin Study
  106. Adherence to physical activity recommendations and physical and mental health risk in people with severe mental illness in Uganda
  107. Self-Reported Cognitive Biases Are Equally Present in Patients Diagnosed With Psychotic Versus Nonpsychotic Disorders
  108. Psychosis, Antipsychotic Medication, and Sexual Dysfunctions
  109. Validity and correlates of the International Physical Activity Questionnaire in first-episode psychosis
  110. Network Approach to Understanding Emotion Dynamics in Relation to Childhood Trauma and Genetic Liability to Psychopathology: Replication of a Prospective Experience Sampling Analysis
  111. The Bitter, Expensive Pill at the End of Life
  112. Interest, competence, appearance, fitness and social relatedness as motives for physical activity in Ugandan outpatients with psychosis
  113. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis
  114. Is sensitivity to daily stress predictive of onset or persistence of psychopathology?
  115. White noise speech illusion and psychosis expression: An experimental investigation of psychosis liability
  116. Lower cardiorespiratory fitness is associated with more time spent sedentary in first episode psychosis: A pilot study
  117. Sedentary Behavior in People Living With HIV: A Systematic Review and Meta-Analysis
  118. Child Maltreatment and Clinical Outcome in Individuals at Ultra-High Risk for Psychosis in the EU-GEI High Risk Study
  119. Perceived Stress and Its Relationship With Chronic Medical Conditions and Multimorbidity Among 229,293 Community-Dwelling Adults in 44 Low- and Middle-Income Countries
  120. Psychological and Biological Validation of a Novel Digital Social Peer Evaluation Experiment (digi-SPEE)
  121. Physical health policies and metabolic screening in mental health care systems of sub-Saharan African countries: a systematic review
  122. Physical activity correlates in people living with HIV/AIDS: a systematic review of 45 studies
  123. Prescribing in schizophrenia and psychosis: Increasing polypharmacy over time
  124. The Relationship Between the Personality Inventory for the DSM-5 (PID-5) and the Psychotic Disorder in a Clinical Sample
  125. Reversing the downward spiral for people with severe mental illness through educational innovations
  126. A systematic review of physical activity policy recommendations and interventions for people with mental health problems in Sub-Saharan African countries
  127. Global physical activity levels among people living with HIV: a systematic review and meta-analysis
  128. Physical activity as a vital sign in patients with bipolar disorder
  129. The prevalence of diabetes mellitus type 2 in people with alcohol use disorders: a systematic review and large scale meta-analysis
  130. Dropout from physical activity interventions in people living with HIV: a systematic review and meta-analysis
  131. Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations
  132. Dropout from physical activity interventions in children and adolescents with attention deficit hyperactivity disorder: A systematic review and meta-analysis
  133. Changes in metabolic parameters in patients with severe mental illness over a 10-year period: A retrospective cohort study
  134. Is autonomous motivation the key to maintaining an active lifestyle in first-episode psychosis?
  135. Physical activity and sedentary behavior in people with bipolar disorder: A systematic review and meta-analysis
  136. The Functional Exercise Capacity Is Associated With Global Functioning in People With Bipolar Disorder
  137. BMI independently relates to glycaemia in patients with severe enduring mental illness (SMI)
  138. Impact of antipsychotic medication on physical activity and physical fitness in adolescents: An exploratory study
  139. Sitting time, physical fitness impairments and metabolic abnormalities in people with bipolar disorder: An exploratory study
  140. Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis
  141. Serious reportable events within the inpatient mental health care: Impact on physicians and nurses
  142. Cardiorespiratory fitness in outpatients with bipolar disorder versus matched controls: An exploratory study
  143. The Prevalence of Metabolic Syndrome in Alcohol Use Disorders: A Systematic Review and Meta-analysis
  144. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders
  145. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis
  146. The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: A systematic review and meta-analysis
  147. Depressive symptoms and muscular fitness contribute independently to the ability to perform daily life activities in people with bipolar disorder
  148. Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review
  149. DSM-5 section III personality traits and section II personality disorders in a Flemish community sample
  150. Genetic Evaluation of Schizophrenia Using the Illumina HumanExome Chip
  151. Concurrent validity of the international physical activity questionnaire in outpatients with bipolar disorder: Comparison with the Sensewear Armband
  152. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics
  153. Physical activity as a vital sign in patients with schizophrenia: Evidence and clinical recommendations
  154. Knowledge of Psychiatric Nurses About the Potentially Lethal Side-Effects of Clozapine
  155. Bone mineral density, osteoporosis, and fractures among people with eating disorders: a systematic review and meta-analysis
  156. A comparison of physical fitness in patients with bipolar disorder, schizophrenia and healthy controls
  157. Type 2 Diabetes Mellitus
  158. Structural Brain Connectivity as a Genetic Marker for Schizophrenia
  159. Attitudes of Psychiatric Nurses about the Request for Euthanasia on the Basis of Unbearable Mental Suffering(UMS)
  160. Reply
  161. Validity of the 6min walk test in outpatients with bipolar disorder
  162. Do Advanced Statistical Techniques Really Help in the Diagnosis of the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotics?
  163. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis
  164. The functional exercise capacity in patients with bipolar disorder versus healthy controls: A pilot study
  165. A Systematic Review of Physical Activity Correlates in Alcohol Use Disorders
  166. Test–retest reliability, feasibility and clinical correlates of the Eurofit test battery in people with bipolar disorder
  167. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics
  168. Health-related quality of life and aerobic fitness in people with schizophrenia
  169. Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness
  170. Promotion of physical health in persons with schizophrenia: can we prevent cardiometabolic problems before they begin?
  171. Prevalence and Predictors of Type 2 Diabetes Mellitus in People With Bipolar Disorder
  172. Aerobic capacity is associated with global functioning in people with schizophrenia
  173. Absence ofN-Methyl-D-Aspartate Receptor IgG Autoantibodies in Schizophrenia
  174. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review
  175. TYPE 2 DIABETES IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A META-ANALYSIS OF PREVALENCE ESTIMATES AND PREDICTORS
  176. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
  177. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
  178. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis
  179. Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
  180. Health-related physical fitness in patients with bipolar disorder vs. healthy controls: An exploratory study
  181. How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview
  182. Promotion of cardiorespiratory fitness in schizophrenia: a clinical overview and meta-analysis
  183. The Construct Validity of the Dutch Personality Inventory for DSM-5 Personality Disorders (PID-5) in a Clinical Sample
  184. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis
  185. Associations Between Metabolic and Aerobic Fitness Parameters in Patients With Schizophrenia
  186. Negative symptoms are associated with lower autonomous motivation towards physical activity in people with schizophrenia
  187. Associative stigma in family members of psychotic patients in Flanders: An exploratory study
  188. Do people with mental illness receive adequate smoking cessation advice? A systematic review and meta-analysis
  189. A Clinical Review of the Treatment of Catatonia
  190. Metabolic syndrome and lung function in schizophrenia: A pilot study
  191. The prevalence and moderators of clinical pain in people with schizophrenia: A systematic review and large scale meta-analysis
  192. Single-subject classification of schizophrenia patients based on a combination of oddball and mismatch evoked potential paradigms
  193. Reliability and clinical correlates of the Astrand–Rhyming sub-maximal exercise test in patients with schizophrenia or schizoaffective disorder
  194. Treatment Continuation and Treatment Characteristics of 3 Long Acting Antipsychotic Medications (Paliperidone Palmitate, Risperidone Microspheres and Haloperidol Decanoate) in Belgium
  195. Somatic Problems and Dual Disorder Patients
  196. Analysis of auto-antibodies in schizophrenia
  197. C.11.01 Metabolic effects in schizophrenia: perception versus reality
  198. Changes in physical activity, physical fitness, self-perception and quality of life following a 6-month physical activity counseling and cognitive behavioral therapy program in outpatients with binge eating disorder
  199. Analysis of pathogenic autoantibodies against the N-methyl-d-aspartate glutamate receptor in schizophrenia
  200. Self-determination and stage of readiness to change physical activity behaviour in schizophrenia
  201. The prevalence of pain in bipolar disorder: a systematic review and large-scale meta-analysis
  202. The functional exercise capacity and its correlates in obese treatment-seeking people with binge eating disorder: an exploratory study
  203. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia
  204. Variability in Working Memory Performance Explained by Epistasis vs Polygenic Scores in theZNF804APathway
  205. Severe mental illness: antipsychotics (revision number 8)
  206. In search of biomarkers for schizophrenia using electroencephalography
  207. Markers of inflammation in schizophrenia: association vs. causation
  208. Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations
  209. No association between genetic or epigenetic variation in insulin growth factors and antipsychotic-induced metabolic disturbances in a cross-sectional sample
  210. The Assessment, Benefits and Delivery of Physical Activity in People with Schizophrenia: A Survey of Members of the International Organization of Physical Therapists in Mental Health
  211. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review
  212. DYSGLYCEMIC SIGNALS IN CHILDREN AND ADOLESCENTS TREATED WITH ANTIPSYCHOTICS FOR THE FIRST TIME
  213. Poster #S175 THE ERYTHROCYTE MEMBRANE LIPID ABNORMALITIES OBSERVED IN SCHIZOPHRENIA PATIENTS SUPPORT THE OXIDATIVE STRESS HYPOTHESIS IN SCHIZOPHRENIA
  214. Poster #T176 THE INCREASED NUMBER OF PHOSPHOLIPID ABNORMALITIES OBSERVED IN THE ERYTHROCYTE MEMBRANE OF SCHIZOPHRENIA PATIENTS IS ASSOCIATED WITH INCREASED PSYCHOPATHOLOGY
  215. Health related quality of life, physical fitness and physical activity participation in treatment-seeking obese persons with and without binge eating disorder
  216. Registration of aggressive incidents in an adolescent forensic psychiatric unit and implications for further practice
  217. The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review
  218. Associations between expiratory spirometry parameters and limitations in daily life activities in patients with schizophrenia
  219. Dysmetabolic features of the overweight patients receiving antipsychotic drugs: A comparison with normal weight and obese subjects
  220. The assessment of creativity in creativity/psychopathology research – a systematic review
  221. Diabetes Risk Potentially Underestimated in Youth and Children Receiving Antipsychotics
  222. Corrections
  223. EPA Guidance on Tobacco Dependence and Strategies for Smoking Cessation in People with Mental Illness
  224. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci
  225. Neurobiological effects of physical exercise in schizophrenia: a systematic review
  226. Creativity and Psychopathology: A Systematic Review
  227. Preliminary study of associative stigma among trainee psychiatrists in Flanders, Belgium
  228. Associations between perceived neighbourhood environmental attributes and self-reported sitting time in patients with schizophrenia: A pilot study
  229. Physical activity and sedentary behaviour in outpatients with schizophrenia: A systematic review and meta-analysis
  230. The importance of self-determined motivation towards physical activity in patients with schizophrenia
  231. The one and the many: effects of the cell adhesion molecule pathway on neuropsychological function in psychosis
  232. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables
  233. There is a need for physiotherapists in the multidisciplinary treatment of schizophrenia
  234. Stigmatization of schizophrenia in Flemish newspapers
  235. Associations between physical activity and the built environment in patients with schizophrenia: a multi-centre study
  236. P.1.j.025 Abnormal cognitive salience but not WCST scores are associated with poor outcome in patients with schizophrenia
  237. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls
  238. End-of-Life (Care) Perspectives and Expectations of Patients With Schizophrenia
  239. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia
  240. Physical Activity Correlates in Persons with Binge Eating Disorder: A Systematic Review
  241. Antipsychotics for acute schizophrenia: making choices
  242. Neurocognition in clinical high risk young adults who did or did not convert to a first schizophrenic psychosis: A meta-analysis
  243. Diabetes, physical activity participation and exercise capacity in patients with schizophrenia
  244. Response to Bartoli et al.
  245. A systematic review of physical therapy interventions for patients with anorexia and bulemia nervosa
  246. The Cognitive Biases Questionnaire for Psychosis (CBQ-P) and the Davos Assessment of Cognitive Biases (DACOBS): Validation in a Flemish sample of psychotic patients and healthy controls
  247. Frequency, Characteristics and Management of Adolescent Inpatient Aggression
  248. Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine
  249. Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia
  250. All SNPs Are Not Created Equal: Genome-Wide Association Studies Reveal a Consistent Pattern of Enrichment among Functionally Annotated SNPs
  251. Screening for diabetes in severe mental illness (revision number 16)
  252. A systematic review on physical therapy interventions for patients with binge eating disorder
  253. CNR1 Gene and Risk of the Metabolic Syndrome in Patients With Schizophrenia
  254. SOCIAL ANXIETY IN PHYSICAL ACTIVITY PARTICIPATION IN PATIENTS WITH MENTAL ILLNESS: A CROSS-SECTIONAL MULTICENTER STUDY
  255. Genetic Schizophrenia Risk Variants Jointly Modulate Total Brain and White Matter Volume
  256. Metabolic Syndrome and Metabolic Abnormalities in Bipolar Disorder: A Meta-Analysis of Prevalence Rates and Moderators
  257. Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs
  258. Schizophrenia genetic variants are not associated with intelligence
  259. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review
  260. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone
  261. An impaired health related muscular fitness contributes to a reduced walking capacity in patients with schizophrenia: a cross-sectional study
  262. Genome-Wide Association Study of Clinical Dimensions of Schizophrenia: Polygenic Effect on Disorganized Symptoms
  263. Associations between sedentary behaviour and metabolic parameters in patients with schizophrenia
  264. Common variant at 16p11.2 conferring risk of psychosis
  265. Replication Study and Meta-Analysis in European Samples Supports Association of the 3p21.1 Locus with Bipolar Disorder
  266. Genetic association study of the P300 endophenotype in schizophrenia
  267. P.8.b.002 The Global Alliance of Mental Illness Advocacy Networks (GAMIAN-Europe) pan European adherence to treatment
  268. Creativity and Psychiatric Illness: The Search for a Missing Link - An Historical Context for Current Research
  269. Genetic Variation Underlying Psychosis-inducing Effects of Cannabis: Critical Review and Future Directions
  270. Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder
  271. Osteoporosis and fracture risk in people with schizophrenia
  272. Eurofit test battery in patients with schizophrenia or schizoaffective disorder: Reliability and clinical correlates
  273. Progressive muscle relaxation in persons with schizophrenia: a systematic review of randomized controlled trials
  274. Authors' reply
  275. Medical outcome of psychiatric inpatients with admission hyponatremia
  276. Safety and tolerability of antipsychotic polypharmacy
  277. Yoga in schizophrenia: a systematic review of randomised controlled trials
  278. SYSTEMATIC EVALUATION OF GUIDELINES FOR MONITORING CARDIO-METABOLIC RISK IN SCHIZOPHRENIA
  279. INTERNATIONAL ORGANIZATION OF PHYSICAL THERAPY IN MENTAL HEALTH-CONSENSUS ON PHYSICAL ACTIVITY WITHIN MULTIDISCIPLINARY REHABILITATION PROGRAMMES FOR MINIMISING CARDIO-METABOLIC RISK IN PATIENTS WITH SCHIZOPHRENIA
  280. Poster #99 CNR1 AND RISK OF THE METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA
  281. Poster #81 GENETIC VARIATION IN ABCB1 ASSOCIATED WITH P300 AMPLITUDE IN SCHIZOPHRENIA
  282. Expression QTL analysis of top loci from GWAS meta-analysis highlights additional schizophrenia candidate genes
  283. Parsing the components of the psychomotor syndrome in schizophrenia
  284. The functional exercise capacity is correlated with global functioning in patients with schizophrenia
  285. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study
  286. Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis
  287. Prediabetes in Patients Treated With Antipsychotic Drugs
  288. A systematic review of correlates of physical activity in patients with schizophrenia
  289. Metaphor interpretation and use: A window into semantics in schizophrenia
  290. Incident somatic comorbidity after psychosis: results from a retrospective cohort study based on Flemish general practice data
  291. Systematic Review of the Benefits of Physical Therapy Within a Multidisciplinary Care Approach for People With Schizophrenia
  292. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: Evidence for a common genetic vulnerability?
  293. The METEOR study
  294. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
  295. Review: people with schizophrenia or other mental illnesses have a lower rate of invasive coronary interventions after acute coronary syndrome
  296. International Organization of Physical Therapy in Mental Health consensus on physical activity within multidisciplinary rehabilitation programmes for minimising cardio-metabolic risk in patients with schizophrenia
  297. Genome-wide association study identifies five new schizophrenia loci
  298. Endogenic and Iatrogenic Diabetes Mellitus in Drug-naïve Schizophrenia: The Role of Olanzapine and its Place in the Psychopharmacological Treatment Algorithm
  299. P.2.e.023 Long -term metabolic effects of aripiprazole adjunctive to lithium, valproate or lamotrigine
  300. Association of the metabolic syndrome with physical activity performance in patients with schizophrenia
  301. C.03.03 Improving patient outcomes: optimising efficacy and safety of antipsychotic treatment
  302. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices
  303. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation
  304. Common variants at VRK2 and TCF4 conferring risk of schizophrenia
  305. Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe
  306. Lack of physical activity during leisure time contributes to an impaired health related quality of life in patients with schizophrenia
  307. Knowledge about HIV in People with Schizophrenia: A General Population Comparison
  308. Efectos adversos metabólicos y endocrinos de los antipsicóticos de segunda generación en niños y adolescentes: una revisión sistemática de ensayos aleatorizados, controlados con placebo y guías de práctica clínica
  309. Quality Assessment of Physical Activity Recommendations Within Clinical Practice Guidelines for the Prevention and Treatment of Cardio-metabolic Risk Factors in People With Schizophrenia
  310. Smoking cessation for patients on clozapine
  311. Dual association of a TRKA polymorphism with schizophrenia
  312. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level
  313. Reliability, minimal detectable changes, practice effects and correlates of the 6-min walk test in patients with schizophrenia
  314. Physical activity participation, functional exercise capacity and self-esteem in patients with schizophrenia
  315. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice
  316. Ventajas y desventajas del tratamiento de combinación con antipsicóticos. Reunión ECNP Consensus, marzo de 2008, Niza
  317. Effects of progressive muscle relaxation on state anxiety and subjective well-being in people with schizophrenia: a randomized controlled trial
  318. Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study
  319. Effects of cannabis use on age at onset in schizophrenia and bipolar disorder
  320. Age at onset of psychotic disorder: Cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction
  321. Prevalence and correlates of seclusion and restraint use in children and adolescents: a systematic review
  322. Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs
  323. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
  324. Relationships between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia
  325. Second-generation antipsychotics and constipation: A review of the literature
  326. The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology
  327. A head-to-head comparison of sertindole and risperidone on metabolic parameters
  328. WITHDRAWN: Maladie cardiovasculaire et diabète chez les sujets souffrant d’une maladie mentale sévère. Déclaration de position de l’European Psychiatric Association (EPA), soutenue par l’European Association for the Study of Diabetes (EASD) et l’Europe...
  329. Editorial for Nordic Journal of Psychiatry
  330. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone
  331. MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study
  332. State anxiety, psychological stress and positive well-being responses to yoga and aerobic exercise in people with schizophrenia: a pilot study
  333. MTHFR and risk of metabolic syndrome in patients with schizophrenia
  334. No association between MTHFR C677T or A1298C and age at onset of schizophrenia
  335. The prevention of deep venous thrombosis in physically restrained patients with schizophrenia
  336. Management of physical health in patients with schizophrenia: practical recommendations
  337. Physical health management in psychiatric settings
  338. Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia
  339. MTHFR GENOTYPE AND DIFFERENTIAL EVOLUTION OF METABOLIC PARAMETERS AFTER INITIATION OF A SECOND GENERATION ANTIPSYCHOTIC
  340. VRINT: A NEWLY DEVELOPED EARLY PSYCHOSIS SERVICE IN BELGIUM
  341. AGE AT ONSET OF PSYCHOSIS IN PATIENTS WITH SCHIZOPHRENIA: EVIDENCE FOR A SEX-DEPENDENT INTERACTION BETWEEN BDNF VAL66MET GENOTYPE AND CANNABIS USE
  342. DO ANTIPSYCHOTIC MEDICATIONS REDUCE OR INCREASE MORTALITY IN SCHIZOPHRENIA? A CRITICAL APPRAISAL OF THE FIN-11 STUDY
  343. IN VIVO PET IMAGING OF CEREBRAL TYPE 1 CANNABINOID RECEPTOR AVAILABILITY IN PATIENTS WITH SCHIZOPHRENIA
  344. PREVALENCE AND SEVERITY OF ANTIPSYCHOTIC RELATED CONSTIPATION
  345. METABOLIC PARAMETERS IN A SUBSET OF PATIENTS IN THE SCOP STUDY
  346. O78 Effets contrastés de l’olanzapine et de la rispéridone sur les taux plasmatiques d’adiponectine chez les patients schizophrènes nouvellement traités
  347. Maladie cardiovasculaire et diabète chez les personnes atteintes d’une maladie mentale sévère
  348. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study
  349. Antipsychotic Use and Risk for Hyperglycemia in Elderly Patients With DM
  350. Cardiometabolic effects of physical activity interventions for people with schizophrenia
  351. Evaluation of the association between insight and symptoms in a large sample of patients with schizophrenia
  352. Mortality in patients with schizophrenia
  353. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (...
  354. Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia
  355. Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent?
  356. Advantages and disadvantages of combination treatment with antipsychotics
  357. The relation between neurocognitive dysfunction and impaired insight in patients with schizophrenia
  358. Prevalence of HIV and hepatitis C infection among patients with schizophrenia
  359. Metabolic syndrome in people with schizophrenia: a review
  360. Cardiovascular disease and diabetes in people with severe mental illness
  361. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder
  362. Traitements neuroleptiques et troubles métaboliques
  363. Psychiatric Diagnosis as an Independent Risk Factor for Metabolic Disturbances
  364. P.3.c.070 Metabolic disorders in patients with schizophrenia treated by antipsychotic drugs in Europe: the METEOR study
  365. P.3.c.071 Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: The METEOR Study
  366. A roadmap to disentangle the molecular etiology of schizophrenia
  367. Incidence of schizophrenia lower in people with type I diabetes
  368. Comorbid Somatic Illnesses in Patients With Severe Mental Disorders
  369. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review
  370. Major Changes in Glucose Metabolism, Including New-Onset Diabetes, Within 3 Months After Initiation of or Switch to Atypical Antipsychotic Medication in Patients With Schizophrenia and Schizoaffective Disorder
  371. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder
  372. Evidence that the COMTVal158Met polymorphism moderates sensitivity to stress in psychosis: An experience-sampling study
  373. P.2.f.004 Clinical and biological features associated with membrane phospholipid distribution in patient with bipolar disorder
  374. C.21.03 Management strategies for patients with a present or emerging health risk
  375. P.2.f.005 Membrane phospholipid distribution: a comparison between patient with schizophrenia and bipolar disorder
  376. Reply to Applicability of the Oral Glucose Tolerance Test in Assessing Prevalence and Incidence of Diabetes Mellitus in Schizophrenia
  377. The association between cognition and functional outcome in first-episode patients with schizophrenia: mystery resolved?
  378. Anticholinergic use in hospitalised schizophrenic patients in Belgium
  379. Abnormal glucose metabolism in patients treated with antipsychotics
  380. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine
  381. Remission criteria for schizophrenia: Evaluation in a large naturalistic cohort
  382. Troubles métaboliques associés aux antipsychotiques atypiques : consensus belge sur la conduite à tenir
  383. A Case Series: Evaluation of the Metabolic Safety of Aripiprazole
  384. Impact of antipsychotic treatment on physical health
  385. Preliminary results of the Belgian lifestyle program ENERGIE on weight in patients with psychiatric disorders
  386. Metabole stoornissen bij patiënten met schizofrenie behandeld met tweedegeneratieantipsychotica
  387. Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder
  388. Premorbid IQ as a predictor for the course of IQ in first onset patients with schizophrenia: A 10-year follow-up study
  389. Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE®
  390. Letter to the Editor
  391. Screening for Diabetes and Other Metabolic Abnormalities in Patients With Schizophrenia and Schizoaffective Disorder
  392. Reversibility of Antipsychotic Treatment–Related Diabetes in Patients With Schizophrenia
  393. The five-factor model of the Positive and Negative Syndrome Scale I: Confirmatory factor analysis fails to confirm 25 published five-factor solutions
  394. The five-factor model of the Positive and Negative Syndrome Scale II: A ten-fold cross-validation of a revised model
  395. Usefulness of glycosylated haemoglobin (HbA1c) to screen for diabetes in patients with schizophrenia
  396. Stereotypy in schizophrenia
  397. Oral glucose tolerance tests in treated patients with schizophrenia.
  398. Schizophrenia: who is at risk? Who is a case?
  399. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication
  400. P.3.d.003 A cross-sectional study of adiponectin in patients with schizophrenia
  401. P.3.c.005 Evaluation of the metabolic safety of aripiprazole
  402. P.3.c.004 Screening for metabolic abnormalities in patients with schizophrenia treated with antipsychotics: are we doing enough?
  403. Pharmacological treatment of hospitalised schizophrenic patients in Belgium
  404. GLUCOSE ABNORMALITIES IN A NON-PSYCHOTIC PATIENT TREATED WITH RISPERIDONE
  405. Belgian consensus on metabolic problems associated with atypical antipsychotics
  406. A study of the family burden of 150 family members of schizophrenic patients
  407. PMH45 MAPPING UTILITY SCORES FROM THE EQ-5D AND SF-6D ONTO THE SCHIZOPHRENIA QUALITY OF LIFE SCALE
  408. Expressed Emotion in the Client-Professional Dyad
  409. The Generic Alternative in Schizophrenia
  410. Psychotic disorders in Prader-Willi syndrome
  411. Risque de diabète sucré sous antipsychotiques atypiques
  412. Safe ECT in a Patient With the Ehlers–Danlos Syndrome
  413. P.2.056 Sound and vision, using popular media to improve knowledge about schizophrenia
  414. P.2.054 Adherence to antipsychotic dosing guidelines in the treatment of hospitalised psychotic patients in Belgium
  415. P.2.055 The influence of antipsychotic drug treatment on anticholinergic use and complexity of medication schemes in hospitalised pschotic patient in Belgium
  416. Guidelines adherence in treated schizophrenic patients
  417. Sound and vision, using popular media to improve knowledge about schizophrenia
  418. Expressed emotion in the client-professional caregiver dyad: are symptoms, coping strategies and personality related?
  419. Expressed emotion
  420. Validation study of PECC (Psychosis Evaluation tool for Common use by Caregivers): Interscale validity and inter-rater reliability
  421. Expressed emotion in staff-patient relationships: the professionals' and residents' perspectives
  422. The Care Perception Questionnaire
  423. Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study
  424. The clinical value of risperidone and olanzapine: A meta-analysis of efficacy and safety
  425. Can we identify the factors influencing the burden on family members of patients with schizophrenia?
  426. Hospitalised schizophrenic patients in Belgium, demographic and clinical data
  427. Interscale validity of PECC, a psychosis evaluation tool for common use by caregivers
  428. Failure to establish linkage on the X chromosome in 301 families with schizophrenia or schizoaffective disorder
  429. Animal models of schizophrenia
  430. A 1-Year Cost-Effectiveness Model for the Treatment of Chronic Schizophrenia with Acute Exacerbations in Belgium
  431. Trail making data in schizophrenic patients
  432. Expressed emotion of professional caregivers of patients with schizophrenia. An exploration of the field
  433. Family stigma: A study of relatives of schizophrenic patients
  434. Intelligence data in first episode psychotic patients 10 years after hospital discharge
  435. Knowledge about schizophrenia in basic caregivers in Belgium
  436. Life chart data in first episode psychotic patients 10 years after hospital discharge
  437. Medication use in hospitalised schizophrenic patients in Belgium
  438. Suïcide en schizofrenie
  439. A genome-wide search for schizophrenia susceptibility genes
  440. Sexual dysfunction: The unspoken side effect of antipsychotics
  441. First-episode schizophrenia, a naturalistic 10 year follow-up study
  442. Introduction of clozapine in Belgium
  443. Health Care Expenditure on Schizophrenia Patients in Belgium
  444. High prevalence of Helicobacter pylori in institutionalized schizophrenic patients
  445. Rehabilitation and Resocialization for the Long-Term Mentally III in Belgium: Description of Services and History of Their Development
  446. High prevalence of helicobacfer pylori in schizophrenic patients
  447. No evidence for more auto-immune pathology in first degree relatives of schizophrenic patients
  448. PQCSPI, an instrument to measure the perception of quality of care for psychotic inpatients
  449. Suicide in Young Schizophrenic Patients During and After Inpatient Treatment
  450. Partial hospitalization at night: the Brussels Nighthospital
  451. Lujan-Fryns syndrome in the differential diagnosis of schizophrenia
  452. Psychotherapy with “New Chronic” Psychotic Patients
  453. The Brussels Night Hospital: A Three-year Follow-up Study
  454. Development of an instrument to measure consumers perception of quality of care for psychotic inpatients
  455. Study of the possible association of HLA class II, CD4, and CD3 polymorphisms with schizophrenia
  456. Treatment of the neuroleptic malignant syndrome with ECT
  457. The function of the brussels night hospital: Dumping, recycling or container?
  458. Management of lethal catatonia with dantrolene sodium
  459. Psychiatric Aspects of Suicidal Behaviour: Schizophrenia